NASDAQ · SERAHealthcareMedical Labs

Sera Prognostics financials

$2.01−0.49%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$81.0K$77.0K$306.0K$268.0K$82.0K
Gross profit-$83.0K-$5.0K$96.0K$75.0K$45.0K
Gross margin−102.5%−6.5%31.4%28.0%54.9%
Operating income-$36.5M-$36.6M-$39.8M-$45.7M-$35.4M
Net income-$31.9M-$32.9M-$36.2M-$44.2M-$35.0M
Net margin−39417.3%−42724.7%−11843.8%−16487.3%−42693.9%
Diluted EPS$-0.67$-0.99$-1.16$-1.43$-2.33
EBITDA-$35.6M-$35.8M-$38.9M-$44.4M-$34.7M
Operating cash flow-$25.6M-$14.2M-$27.2M-$34.6M-$31.6M
Free cash flow-$26.3M-$14.2M-$27.3M-$35.4M-$32.9M
Diluted shares47.7M33.2M31.2M30.9M15.0M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$3.9M$4.0M$3.9M$29.9M$58.9M
Short-term investments$35.3M$42.2M$45.2M$52.8M$46.2M
Total debt$2.0K$196.0K$636.0K$1.1M$128.0K
Total assets$101.9M$72.6M$95.4M$116.3M$147.0M
Total liabilities$26.5M$24.8M$25.3M$17.4M$8.5M
Shareholders' equity$75.4M$47.8M$70.2M$98.9M$138.6M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology